Log in

NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

$50.70
+0.91 (+1.83 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$49.05
Now: $50.70
$51.12
50-Day Range
$38.10
MA: $43.64
$49.79
52-Week Range
$25.01
Now: $50.70
$174.73
Volume590,405 shs
Average Volume634,279 shs
Market Capitalization$2.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.67
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
SAGE Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.87 million
Book Value$18.23 per share

Profitability

Net Income$-680,240,000.00
Net Margins-7,406.75%

Miscellaneous

Employees637
Market Cap$2.63 billion
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$50.70
+0.91 (+1.83 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

How has SAGE Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has increased by 19.9% and is now trading at $50.70.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of SAGE Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SAGE Therapeutics
.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for SAGE Therapeutics
.

How can I listen to SAGE Therapeutics' earnings call?

SAGE Therapeutics will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($3.17) by $0.73. The biopharmaceutical company earned $2.29 million during the quarter, compared to analyst estimates of $2.81 million. SAGE Therapeutics had a negative return on equity of 63.13% and a negative net margin of 7,406.75%. The firm's revenue for the quarter was up 391.6% compared to the same quarter last year. During the same period last year, the business posted ($3.37) earnings per share.
View SAGE Therapeutics' earnings history
.

What price target have analysts set for SAGE?

17 brokerages have issued 12 month price targets for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $82.11 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price.
View analysts' price targets for SAGE Therapeutics
.

Has SAGE Therapeutics been receiving favorable news coverage?

Media stories about SAGE stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about SAGE Therapeutics
.

Who are some of SAGE Therapeutics' key competitors?

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the following people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Asymmetry Capital Management L.P. (0.38%), Swiss National Bank (0.22%), Russell Investments Group Ltd. (0.18%), UBS Group AG (0.12%), WINTON GROUP Ltd (0.11%) and Quantitative Systematic Strategies LLC (0.04%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for SAGE Therapeutics
.

Which institutional investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, and Arizona State Retirement System.
View insider buying and selling activity for SAGE Therapeutics
.

Which institutional investors are buying SAGE Therapeutics stock?

SAGE stock was bought by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Russell Investments Group Ltd., WINTON GROUP Ltd, UBS Group AG, Swiss National Bank, Quantitative Systematic Strategies LLC, Virtus ETF Advisers LLC, and XTX Markets LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for SAGE Therapeutics
.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $50.70.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $2.63 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is www.sagerx.com.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.